BRIEF-Mylan finalizes settlement on Medicaid rebate classification for Epipen

Aug 17 (Reuters) – Mylan NV:

* Mylan finalizes settlement agreement on Medicaid rebate classification for Epipen auto-injector

* Will reclassify Epipen auto-injector for purposes of Medicaid drug rebate program​

* Settlement resolves claims relating to classification of Epipen auto-injector & Epipen Jr auto-injector for purposes of Medicaid drug rebate program​

* Subsidiaries signed agreement finalizing Medicaid drug rebate settlement that company announced on Oct 7, 2016 for $465 million​

* Mylan will ‍pay rebate applicable to innovator products effective as of April 1, 2017​

* Settlement does not contain an admission or finding of wrongdoing​

* Mylan has also entered into a corporate integrity agreement with Office of Inspector General of Department Of Health and Human Services​

* Settlement provides for resolution of all potential medicaid rebate liability claims by federal government, potential claims by certain hospitals Source text for Eikon: Further company coverage: (Reporting by Sharnya G)

Go to Source